Frédéric Vanhoutte

1.3k citations
35 papers · 983 · h-index 15

Impact in

  • Rheumatology top 2%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research
  • Hematology top 5%
    • Autoimmune and Inflammatory Disorders Research

Papers in

Co-authors
Annegret Van der Aa (10 shared papers)Pille Harrison (4 shared papers)Chantal Tasset (4 shared papers)Maria Greenwald (4 shared papers)Minodora Mazur (4 shared papers)Mykola Stanislavchuk (3 shared papers)Florence Namour (9 shared papers)René Westhovens (4 shared papers)
Journals
Annals of the Rheumatic Diseases (8 papers)Journal of Crohn s and Colitis (3 papers)British Journal of Dermatology (3 papers)Clinical and Translational Science (2 papers)British Journal of Clinical Pharmacology (2 papers)
Partner nations
BelgiumUnited StatesUkraine

In The Last Decade

Frédéric Vanhoutte

34 papers receiving 966 citations

Peers

Frédéric Vanhoutte
Comparison fields: 5 of 86
  • Rheumatology 390
  • Hematology 186
  • Genetics 161
  • Immunology 219
  • Oncology 242
Replace Debra M. Meyer with:
Debra M. Meyer United States
Naresh Punwani United States
Michael I. Jesson United States
René Galien Belgium
Lichen Teng China
P. Brent Ferrell United States
Gabriele Stefanzl Austria
Cynthia Kuk Canada
Anne Blackwood‐Chirchir United States
Nicola Calvani Italy
Frédéric Vanhoutte relative to Debra M. Meyer United States Debra M. Meyer's profile →
Citations per field
00.5×1.5×2×
Debra M. Meyer · 1×
Citations per year

Countries citing papers authored by Frédéric Vanhoutte

Since Specialization
Citations

This map shows the geographic impact of Frédéric Vanhoutte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Vanhoutte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Vanhoutte more than expected).

Fields of papers citing papers by Frédéric Vanhoutte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Vanhoutte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Vanhoutte. The network helps show where Frédéric Vanhoutte may publish in the future.

Co-authors

The 25 scholars most cited alongside Frédéric Vanhoutte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frédéric Vanhoutte Line = papers co-authored together Frédéric Vanhoutte links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
Annals of the Rheumatic Diseases ·René Westhovens, Peter C. Taylor, Rieke Alten, Д. Е. Павлова, Favio Enríquez-Sosa, Minodora Mazur, Maria Greenwald, Annegret Van der Aa, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison
2016184
2
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Joel M. Kremer, L Ponce, Regina Cseuz, O. V. Reshetko, Mykola Stanislavchuk, Maria Greenwald, Annegret Van der Aa, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison
2016176
3
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study
British Journal of Dermatology ·M. Bhushan, A. David Burden, Kathleen McElhone, R. L. James, Frédéric Vanhoutte, C.E.M. Griffiths
200188
4
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Arthritis & Rheumatology ·Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namour, René Galien, Luc Meuleners, Gerben van ‘t Klooster
201761
5
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Clinical Pharmacology in Drug Development ·Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe, John van Duzer, Kathleen C. M. Campbell, Frédéric Vanhoutte
201958
6
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
Investigational New Drugs ·Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, Annegret Van der Aa, Giocondo Lorenzon, Florence Namour, Philippe Pujuguet, Sophie Darquenne, Filip Y.F. de Vos, Tom J. Snijders, Emile E. Voest, Jan H.M. Schellens, Martijn P. Lolkema
201653
7
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
British Journal of Clinical Pharmacology ·Florence Namour, René Galien, Tim Van Kaem, Annegret Van der Aa, Frédéric Vanhoutte, Johan Beetens, Gerben van’t Klooster
201647
8
Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study
British Journal of Dermatology ·C.J. Verfaille, Frédéric Vanhoutte, C Blanchet‐Bardon, Maurice A. M. Van Steensel, Peter M. Steijlen
200740
9
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
The Journal of Clinical Pharmacology ·Frédéric Vanhoutte, Liang Su, Marcella Ruddy, An Sha Zhao, Tiera Drewery, Yuhuan Wang, Richard DelGizzi, Eduardo Forleo‐Neto, Manoj Rajadhyaksha, Gary Herman, John D. Davis
202036
10
Treatment of psoriasis with oral liarozole: a dose‐ranging study
British Journal of Dermatology ·J. Berth‐Jones, George Todd, P.E. Hutchinson, Kristian Thestrup‐Pedersen, Frédéric Vanhoutte
200027
11
Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
Antimicrobial Agents and Chemotherapy ·Elina Berliba, Maxim Bogus, Frédéric Vanhoutte, P.-J. Berghmans, Steven S. Good, Adel Moussa, Keith Pietropaolo, Robert L. Murphy, Xiao-Jian Zhou, Jean‐Pierre Sommadossi
201925
12
A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
Clinical Pharmacology in Drug Development ·Andi Leubitz, Frédéric Vanhoutte, Ming‐yi Hu, Kaela M. Porter, Efrat Gordon, K Tencer, Kathleen C. M. Campbell, Kate Banks, Tom Haverty
202123
13
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
EBioMedicine ·Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, Liesbeth Haspeslagh, Xin Cao, Keith Boundy, Antonios O. Aliprantis, M. A. Rodriguez Dávila, Jonathan Hartzel, Jianing Li, Mac McGuire, Katrin Ramsauer, Yvonne Tomberger, Roland Tschismarov, Deborah D. Brown, Weifeng Xu, Jeffrey R. Sachs, Kevin L. Russell, S. Aubrey Stoch, Eseng Lai
202218
14
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Annals of the Rheumatic Diseases ·René Westhovens, Filip De Keyser, Д. Г. Рекалов, Е. Л. Насонов, Johan Beetens, Annegret Van der Aa, Piet Wigerinck, Florence Namour, Frédéric Vanhoutte, Patrick Durez
201218
15
Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers
Clinical Infectious Diseases ·Oliver Ackaert, Frédéric Vanhoutte, Nathalie Verpoorten, Annemie Buelens, Sophie Lachau‐Durand, Lieve Lammens, Richard M. W. Hoetelmans, Marnix Van Loock, Guillermo Herrera‐Taracena
202318
16
P610 Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
Journal of Crohn s and Colitis ·Séverine Vermeire, Walter Reinisch, Dorota Waśko−Czopnik, Tim Van Kaem, Julie Desrivot, Frédéric Vanhoutte, Johan Beetens
201714
17
Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects
British Journal of Clinical Pharmacology ·Christian Funck‐Brentano, Mathieu Felices, Nathalie Le Fur, Corinne Dubourdieu, Pierre Desché, Frédéric Vanhoutte, Guillaume Voiriot
202013
18
OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial
Annals of the Rheumatic Diseases ·Frédéric Vanhoutte, Minodora Mazur, Florence Namour, Annegret Van der Aa, Piet Wigerinck, Gerben A.E. van 't Klooster
201213
19
THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study
Annals of the Rheumatic Diseases ·Arthur Kavanaugh, L Ponce, Regina Cseuz, O. V. Reshetko, Mykola Stanislavchuk, Maria Greenwald, Aa A. Van der, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison
201611
20
OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study
Annals of the Rheumatic Diseases ·René Westhovens, R. Alten, Д. Е. Павлова, F.E. Enriquez Sosa, Minodora Mazur, Maria Greenwald, Aa A. Van der, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison
201610

About Frédéric Vanhoutte

Frédéric Vanhoutte is a scholar working on Rheumatology, Molecular Biology, Genetics, Immunology and Oncology, having authored 35 papers that have together received 983 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (9 papers), Rheumatoid Arthritis Research and Therapies (8 papers), Cytokine Signaling Pathways and Interactions (4 papers), Inflammatory Bowel Disease (3 papers), Systemic Lupus Erythematosus Research (3 papers), Biochemical Analysis and Sensing Techniques (2 papers), Cell Adhesion Molecules Research (2 papers) and Autoimmune and Inflammatory Disorders Research (2 papers). The work is most often cited by research in Rheumatology (390 citations), Hematology (186 citations), Genetics (161 citations), Immunology (219 citations) and Oncology (242 citations). Frédéric Vanhoutte has collaborated with scholars based in Belgium, United States and Ukraine. Frequent co-authors include Annegret Van der Aa, Pille Harrison, Chantal Tasset, Maria Greenwald, Minodora Mazur, Mykola Stanislavchuk, Florence Namour, René Westhovens, Rieke Alten and Regina Cseuz. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Crohn s and Colitis, British Journal of Dermatology, Clinical and Translational Science and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debra M. MeyerBreakdown of academic impact, for papers by Naresh PunwaniBreakdown of academic impact, for papers by Michael I. JessonBreakdown of academic impact, for papers by René GalienBreakdown of academic impact, for papers by Lichen TengBreakdown of academic impact, for papers by P. Brent FerrellBreakdown of academic impact, for papers by Gabriele StefanzlBreakdown of academic impact, for papers by Cynthia KukBreakdown of academic impact, for papers by Anne Blackwood‐ChirchirBreakdown of academic impact, for papers by Nicola Calvani